Rovalpituzumab tesirine, a DLL3-targeted antibody-drug...

The Lancet Oncology 2017 / 01 Vol. 18; Iss. 1

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, Bhed
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30565-4
Date:
January, 2017
File:
PDF, 300 KB
english, 2017
Conversion to is in progress
Conversion to is failed